Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

French drugmaker Sanofi said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high costs.

Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%

The French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.

Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk

Sanofi SNY FR:SAN said Thursday that it will cut the U.S. list price of Lantus by 78%, and it will also cap out-of-pocket costs at $35 for the same insulin for people with commercial health insurance, starting in 2024. The French drugmaker's announcement follows the reduction of insulin prices at Eli Lilly LLY and Novo Nordisk NVO DK:NOVO.B.

Sanofi to cap price of Lantus insulin at $35

Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Provention Bio Inc

Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.

This biopharma stock jumped over 250% on Monday: what happened?

Costco

D.R. Horton

First Republic

Lennar

Pfizer

Seagen

SVB Financial Group

Target

Toll Brothers

Walmart

SPDR S&P Homebuilders ETF

Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions

French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or a total equity value of about $2.9 billion. Provention Bio's stock surged more than 250% in early trading on Monday, while shares of Sanofi slipped 1%.

Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.

Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal

Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.

Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)

The biopharmaceutical company agrees to be acquired by France's Sanofi for $25 a share, or about $2.9 billion.

Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi

French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with an equity value of $2.9 billion. The deal will allow Sanofi to add to its portfolio, TZIELD, which was approved in the U.S. last year as the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).

Sanofi to buy Provention Bio in deal worth $2.9 billion

France's Sanofi has agreed to acquire Provention Bio for $2.9 billion to bolster its work on type 1 diabetes therapy and to strengthen its drug pipeline following development setbacks.

Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal

Sanofi to acquire Proventio n Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

AstraZeneca

Johnson & Johnson

Novo Nordisk

Novartis

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.

5 Large Drug Stocks to Watch as Sector Picks Up in 2023

Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA

Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies. The post Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race appeared first on Investor's Business Daily.

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race

Bayer AG

Anheuser-Busch InBev

Experian PLC

Novozymes A/S

Reckitt Benckiser Group PLC

Roche Holding AG

Tencent Holdings Limited

Toronto-Dominion Bank

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The March 2023 Heat Map

Regeneron Pharmaceuticals

Dupixent ® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

DuPont de Nemours

Ecopetrol

Emerson Electric

Roper Technologies

Stellantis N.V. 

United Microelectronics

When the game's on the line, sometimes you need to call up your most experienced players, which segues into this discussion of blue-chip stocks to buy. Any sports fan realizes that age comes for every athlete, including the great Tom Brady.

7 Blue-Chip Stocks to Buy for Quality-Focused Investors

Altuviiio is indicated to prevent and control bleeding episodes in hemophilia patients. In 2022, Sanofi saw business EPS grow more than 17% year over year.

Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval

Completed XTEND-Kids P hase 3 study strengthens potential of ALTUVIIIO™ to red e fin e expectations for treatment of children

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children

Advanced Semiconductor Engineering

Concrete Pumping Holdings

JinkoSolar Holding

Universal Forest Products

We have screened value stocks JKS, UFPI, ASX, BBCP and SNY based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

5 Stocks With Amazingly Low EV-to-EBITDA Ratios to Snap Up

FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal, impacting 2022 IFRS net income; no change on business net income (non-IFRS)

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

New Phase 3 data presented at WORLDSymposium ™ reinforce Nexviazyme ® ( avalg lu cosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

News for Sanofi Stock (SNY)